UTS site search

Our research

Pharmaceutical Benefits Advisory Committee (PBAC)

Key objective
To provide high quality, accurate and independent critiques of pharmaceutical submissions for the Pharmaceutical Benefit Advisory Committee

The Pharmaceutical Benefits Advisory Committee (PBAC) is an independent statutory body established to make recommendations and give advice to the Minister about which drugs should listed on the Pharmaceutical Benefits Scheme. PBAC makes recommendations based on the effectiveness and cost-effectiveness of new drugs.

In 2009, CHERE won a competitive tender to become an independent evaluator for PBAC. CHERE evaluates and prepares high quality commentaries on a number of major submissions each year. The evaluations involve analysis and review of complex clinical and economic data, including modelled analyses. The work is cyclical and has to be completed within a tight, strictly adhered to timeframe corresponding to each PBAC meeting, which are held every four months.

Funding source
Department of Health and Ageing

CHERE staff
Stephen GoodallPaula Cronin, Jody Church, Bonny ParkinsonRebecca ReeveChanghao HouPhil HaywoodJennifer HoultramSopany SaingElena Meshcheriakova, Marion Haas